SCHEMBL4018968

SCHEMBL4018968

Cc1cccc(/C=C/C(=O)NCCc2c(C)[nH]c3c(F)ccc(C)c23)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC4 P56524 3/20 0.44
MEF2D Q14814 2/20 0.44
HPGD P15428 3/20 0.43
ALDH1A1 P00352 1/20 0.43
MMP1 P03956 3/20 0.41
MMP2 P08253 3/20 0.41
MMP9 P14780 3/20 0.41
MAPT P10636 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HDAC1 Q13547 3/20 0.41
HDAC2 Q92769 3/20 0.41
HDAC6 Q9UBN7 3/20 0.41
HDAC3 O15379 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4017742 0.91 MMP1 (0.53) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4015068 0.91 MEN1 (0.44) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4017825 0.90 MMP1 (0.50) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4754641 0.90 MEN1 (0.42) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4667869 0.90 MEN1 (0.42) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4669534 0.90 HPGD (0.43) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4015839 0.89 MEN1 (0.44) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4668491 0.89 KDM4E (0.48) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4017504 0.89 HPGD (0.53) MEN1KMT2AHDAC4MEF2DHPGD
SCHEMBL4752607 0.89 KDM4E (0.48) MEN1KMT2AHDAC4MEF2DHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014287-A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
EP-2014287-A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed